At The Forefront Of Regulatory Change – BIVDA’s Ashleigh Batchen
IVDs Regulation Is Like A Jigsaw With An Ever Growing Number Of Pieces
Executive Summary
In Vivo Rising Leader Ashleigh Batchen has packed a lot of experience of medical device diagnostic regulatory issues into a few short years at the British In Vitro Diagnostics Association and before that the UK MHRA. Her advocacy offers vital support to the IVD industry at the busiest time in UK – and EU – regulatory history.
You may also be interested in...
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.